Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have been assigned an average recommendation of "Hold" from the nineteen brokerages that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.81.

SAGE has been the subject of a number of analyst reports. Wedbush reiterated a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Wall Street Zen downgraded Sage Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday. Scotiabank cut their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th.

Sage Therapeutics Stock Down 2.8%

SAGE stock traded down $0.19 during mid-day trading on Friday, reaching $6.61. 716,527 shares of the company traded hands, compared to its average volume of 1,195,947. The stock has a market cap of $413.92 million, a price-to-earnings ratio of -1.00 and a beta of 0.20. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $13.47. The firm's 50 day moving average price is $7.35 and its 200 day moving average price is $6.73.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Sage Therapeutics's revenue for the quarter was up 78.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.80) EPS. On average, analysts anticipate that Sage Therapeutics will post -3.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Sage Therapeutics by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 5,077,288 shares of the biopharmaceutical company's stock worth $40,364,000 after purchasing an additional 239,119 shares during the period. Caligan Partners LP bought a new stake in shares of Sage Therapeutics in the 4th quarter worth approximately $16,575,000. TIG Advisors LLC bought a new stake in shares of Sage Therapeutics in the 1st quarter worth approximately $21,722,000. Millennium Management LLC raised its holdings in shares of Sage Therapeutics by 8.3% in the 4th quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company's stock worth $8,817,000 after purchasing an additional 124,720 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in shares of Sage Therapeutics in the 4th quarter worth approximately $7,540,000. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.